Skip to main content

BD Reports 12-Percent Rise in Fiscal Q3 Sales; R&D, Profit Post Gains

NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal third-quarter revenues rose 11.6 percent as R&D spending climbed 21 percent and profit grew 19 percent.
 
Total receipts for the three months ended June 30 increased to $1.63 billion from $1.46 billion year over year.
 
BD said revenues from its Diagnostics segment grew 15 percent to $492 million, while Biosciences revenue rose 13 percent to $258 million. Revenue from the Medical segment rose 10 percent to $882 million.  
 
R&D spending for the quarter rose to $93 million from $77 million year over year.
 
Profits for the quarter increased to $245 million from $206 million in the year-ago period.
 
The company did not disclose its balance sheet for the period.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.